Advertisement

FOS expression in blood as a LDL-independent marker of statin treatment

      Abstract

      Objectives

      The expression of FOS, a gene critical for monocyte and macrophage function, can be inhibited by statins through the disruption of a cholesterol-independent signaling pathway. In this pilot study, we hypothesized that blood FOS mRNA levels will be sensitive to statin treatment independent of LDL cholesterol levels.

      Methods

      Three cohorts at increased risk of or with cardiovascular disease (CVD) were studied. Blood FOS mRNA levels were measured before and after statin treatment or in patients under stable treatment.

      Results

      Statin treatment for three months significantly reduced blood FOS mRNA and LDL cholesterol levels. However, in subjects with similar LDL levels achieved by different doses of long term statin treatment, there was an inverse relationship between statin dose and FOS expression.

      Conclusions

      FOS mRNA levels appear to be a sensitive marker of statin treatment that is dissociated from cholesterol levels.

      Abbreviations:

      CAD (coronary artery disease), CVD (cardiovascular diseases), FOS (Finkel–Biskis–Jinkins osteosarcoma gene), HMG CoA reductase (3-hydroxy-3-methylglutaryl coenzyme A reductase), hsCRP (high sensitivity C-reactive protein), statin (HMG CoA reductase inhibitor)

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Liao J.K.
        • Laufs U.
        Pleiotropic effects of statins.
        Annu Rev Pharmacol Toxicol. 2005; 45: 89-118
        • Jain M.K.
        • Ridker P.M.
        Anti-inflammatory effects of statins: clinical evidence and basic mechanisms.
        Nat Rev Drug Discov. 2005; 4: 977-987
        • Robinson J.G.
        • Smith B.
        • Maheshwari N.
        • Schrott H.
        Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis.
        J Am Coll Cardiol. 2005; 46: 1855-1862
        • Ross R.
        Atherosclerosis—an inflammatory disease.
        N Engl J Med. 1999; 340: 115-126
        • Libby P.
        • Ridker P.M.
        • Hansson G.K.
        Inflammation in atherosclerosis: from pathophysiology to practice.
        J Am Coll Cardiol. 2009; 54: 2129-2138
        • Seo D.
        • Ginsburg G.S.
        • Goldschmidt-Clermont P.J.
        Gene expression analysis of cardiovascular diseases: novel insights into biology and clinical applications.
        J Am Coll Cardiol. 2006; 48: 227-235
        • Chittenden T.W.
        • Sherman J.A.
        • Xiong F.
        • et al.
        Transcriptional profiling in coronary artery disease: indications for novel markers of coronary collateralization.
        Circulation. 2006; 114: 1811-1820
        • Sinnaeve P.R.
        • Donahue M.P.
        • Grass P.
        • et al.
        Gene expression patterns in peripheral blood correlate with the extent of coronary artery disease.
        PLoS One. 2009; 4: e7037
        • Liebermann D.A.
        • Gregory B.
        • Hoffman B.
        AP-1 (Fos/Jun) transcription factors in hematopoietic differentiation and apoptosis.
        Int J Oncol. 1998; 12: 685-700
        • Patino W.D.
        • Mian O.Y.
        • Kang J.G.
        • et al.
        Circulating transcriptome reveals markers of atherosclerosis.
        Proc Natl Acad Sci USA. 2005; 102: 3423-3428
        • Wang Z.Q.
        • Ovitt C.
        • Grigoriadis A.E.
        • Mohle-Steinlein U.
        • Ruther U.
        • Wagner E.F.
        Bone and haematopoietic defects in mice lacking c-fos.
        Nature. 1992; 360: 741-745
        • Lavezzi A.M.
        • Milei J.
        • Grana D.R.
        • Flenda F.
        • Basellini A.
        • Matturri L.
        Expression of c-fos, p53 and PCNA in the unstable atherosclerotic carotid plaque.
        Int J Cardiol. 2003; 92: 59-63
        • Marinissen M.J.
        • Chiariello M.
        • Tanos T.
        • Bernard O.
        • Narumiya S.
        • Gutkind J.S.
        The small GTP-binding protein RhoA regulates c-jun by a ROCK-JNK signaling axis.
        Mol Cell. 2004; 14: 29-41
        • Grundy S.M.
        • Cleeman J.I.
        • Merz C.N.
        • et al.
        Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
        Circulation. 2004; 110: 227-239
        • Biesecker L.G.
        • Mullikin J.C.
        • Facio F.M.
        • et al.
        The ClinSeq project: piloting large-scale sequencing for research in genomic medicine.
        Genome Res. 2009; 19: 1665-1674